Children ‘ s Cronn ‘ s disease, as a chronic intestinal disease, has serious implications for their growth and quality of life. In recent years, some progress has been made in its treatment, but many challenges remain.
At present, drug treatment is the main means of child cron disease. Amino-water canyon acids, such as mesalazine, are often used in mild and moderate cases to mitigate symptoms by inhibiting intestinal inflammation. For children with moderate and severe conditions, sugar cortex hormones can reduce inflammation rapidly, but the long-term use of side effects, such as developmental effects and osteoporosis, is evident. Immunosuppressants, such as sulfur, ammonium butterflies, can be used for hormonal dependence or incurable cases, and function by regulating the immune system, but there are risks such as bone marrow inhibition, requiring close monitoring of blood protocol and liver function. The use of biological agents has been an important breakthrough in recent years, with the Inflisi mono-drug-specific interdiction factors, which have had a significant impact on children with ineffective traditional treatment or with serious complications, but which are expensive and can increase the risk of infection and require rigorous assessment and monitoring during use.
Nutritional support is also crucial in the treatment of children with Crohn. There is a lack of nutrition as intestinal inflammation often leads to indigestion and absorption disorders. Therefore, the development of individualized nutrition programmes, such as the introduction of factor diets or intestinal nutrients, not only improves nutritional status and fosters growth and development, but also has a certain anti-inflammation effect that induces the mitigation of mildly active diseases, some of which can be achieved over the long term through simple nutritional treatment.
Surgery is a choice when the medication is ineffective or when serious complications such as intestine infarction, perforation, haemorrhage, etc. Common surgery methods include intestinal ectoptomy, narrow-forming, etc., but have a high rate of post-operative re-emergence, which may affect intestinal function and nutritional absorption, and therefore still require drug maintenance treatment and close follow-up.
Despite the increasing availability of treatment, the treatment of children with Crohn ‘ s disease still faces many difficulties. On the one hand, drug side effects limit long-term treatment effects, and balancing efficacy and safety is a challenge for clinical doctors. On the other hand, the high cost of treatment places a heavy financial burden on families and societies and limits access to the best treatment programmes for some children. In addition, the current treatment focuses more on the control of symptoms and inflammations, which make it difficult to achieve a complete cure, with children often facing relapse and long-term survival.
In the future, the treatment of child Crohn ‘ s disease is expected to usher in a new breakthrough. New biological agents and small molecular drugs are being developed and may have better efficacy and safety. The development of precision medicine will contribute to the development of more accurate treatment programmes based on individual characteristics such as the genetics of the infected child, immunization, etc., to improve the effectiveness of treatment and reduce the side effects. At the same time, as intestinal microecological studies deepen, treatment of diseases through the regulation of intestinal strains is also possible. In addition, the multidisciplinary collaborative treatment model will be further refined to integrate multidisciplinary capacities such as paediatrics, digestives, nutrition and surgery, to provide more comprehensive, personalized treatment services for children with disabilities and to improve the long-term planning of children with disabilities so that they can return to normal life and learning.
